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Abstract
Background: Oral cancer is the sixth most common malignancy worldwide with a mortality rate that is higher
than many other cancers. Death usually occurs as a result of local invasion and regional lymph node metastases.
Decorin is a multifunctional proteoglycan of the extracellular matrix that affects the biology of various types of
cancer. Previously; we have shown that decorin is aberrantly expressed in the nucleus in human dysplastic oral
keratinocytes (DOK) and malignant squamous cells carcinoma (SCC-25) and human biopsy tissues. In this study, we
examined the role of nuclear decorin in oral cancer progression.
Materials and methods: We have used a post-transcriptional gene silencing (RNA interference) approach to stably
knockdown nuclear decorin gene expression in DOK and SCC-25 cells using a specific shRNA plasmid and a
combination of immunological and molecular techniques to study nuclear decorin function in these oral epithelial
cell lines.
Results: More than 80% decorin silencing/knockdown was achieved as confirmed by real time PCR and western blot
analysis in both DOK and SCC-25 cells. This RNA interference-mediated knockdown of nuclear decorin expression
resulted in significantly reduced invasion and migration in these cell lines as measured by Matrigel™ coated and
uncoated Trans well chamber assays respectively. Decorin silencing also resulted in reduced IL-8 mRNA and proteins
levels in these cell lines. Culturing decorin silenced DOK and SCC-25 cells, with recombinant human IL-8 or IL-8
containing conditioned medium from respective un-transfected cells for 24 h prior to migration and invasion
experiments, resulted in the salvation of reduced migration and invasion phenotype. Furthermore, we found that
nuclear localized decorin interacts with EGFR in the nuclear fractions of both DOK and SCC-25 cells. Interestingly,
EGFR (trans) activation has previously been shown to be involved in IL-8 production in various epithelia.
Conclusions: Taken together, our results indicate that nuclear localized decorin plays an important role in migration
and invasion of oral cancer cells and thus may present as a novel potential target for the treatment of oral cancer.
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Background
Oral squamous cell carcinoma (SCC) is the sixth most
common cancer in the world [1,2]. It accounts for
roughly quarter of a million newly diagnosed cancers
worldwide, and is the most frequently diagnosed cancer
in developing countries of the world [3,4]. Despite
improvements in surgical techniques, radiation therapy
protocols, and chemotherapeutic regimens [5], the over-
all five year survival rate for oral SCC remains at 50%
and has not significantly improved in the past 30 years.
Morbidity associated with the disease further affects the
quality of life in patients as nutrition, speech and gen-
eral immunity gets compromised as well. In oral cancer
patients, death usually occurs as a result of local inva-
sion into the stromal tissue of head & neck and cervical
lymph node metastases [6,7].
Decorin is a member of small leucine-rich repeat pro-
teoglycans (SLRPs) family and is primarily synthesized
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family are structurally related and play major roles in
the organization of the extracellular matrix (ECM) and
the regulation of cell behaviour [9]. SLRPs have a 40-50
kDa protein core with a central leucine rich repeat
(LRR) domains characterized by a common molecular
architecture adapted for protein-protein interaction [10].
Decorin is a known ligand for epidermal growth factor
receptor (EGFR) [11,12].
Decorin is normally present in the extracellular stromal
compartment and has been shown to restrain growth of
many tumor cells [13] by down-regulating the epidermal
growth factor receptor (EGFR) [9]. The underlying
mechanism is not fully understood but includes direct dec-
orin binding to EGFR followed by sustained internalization
of EGFR via caveolar-mediated endocytosis [14] and the
apoptosis triggering via caspase-3 activation [15]. Although,
d e c o r i ni se x p r e s s e di nt u m o rs t r o m ab u ti t ’s rarely
expressed by cancer cells and tissues themselves as has
been demonstrated by analysis of a variety of tumors
including colon, pancreas, prostate, lung, ovarian, breast
cancer [16-19]. However, studies by us and others have
shown that decorin is expressed by oral squamous cell car-
cinoma and osteosarcoma cells [20,21]. Osteosarcoma cells
were shown to be insensitive to decorin-induced growth
arrest, rather decorin seemed to be beneficial, since it was
necessary for osteosarcoma cell migration [22].
Interleukin (IL)-8, a proinflammatory cytokine of the
CXC chemokine family that was originally classified as a
neutrophil chemoattractant, has been shown to play a sig-
nificant role in tumor progression and metastasis in a vari-
ety of human cancers, including oral cancers [23,24]. This
chemokine activates multiple intracellular signalling path-
ways downstream of two cell-surface, G protein coupled
receptors; CXCR1 and CXCR2. IL-8 biologic activity in
tumors and the tumor microenvironment contributes to
cancer progression through its functions in the regulation
of angiogenesis, cancer cell growth and survival, tumor
cell invasion and metastasis, leukocyte infiltration and
modification of immune responses [23,24]. Exogenous
decorin has been shown to induce IL-8 production in
endothelial cells [25].
Previously; we have shown that decorin is aberrantly
expressed as well as translocated to the nucleus in dys-
plastic oral keratinocytes (DOK) and malignant squa-
mous cell carcinoma (SCC-25) and in oral cancer biopsy
tissue [20]. In the present study; using shRNA expression
plasmid mediated in vitro stable gene silencing in DOK
and SCC-25 cells, we demonstrate that nuclear localized
decorin knockdown suppresses migration and invasion in
dysplastic and malignant oral epithelial cells. Our data
also indicates that reduced migration and invasion phe-
notype of these cells is mediated by IL-8 modulation as
demonstrated by supplementation/rescue experiments.
Furthermore, we show here that this nuclear localized
decorin interacts with EGFR in the nuclear fractions of
both DOK and SCC-25 cells, thus providing the first
indication of a unique phenomenon in oral epithelial
cells.
Materials and methods
Cell Lines and culture conditions
Oral epithelial origin, premalignant- Dysplastic Oral
Keratinocyte (DOK) and malignant- Squamous Carci-
noma Cell (SCC-25) lines were routinely maintained in
DMEM/F12 (Hyclone, Logan, Utah) supplemented with
10% Foetal Calf Serum for use as in vitro model in our
studies, as described previously [26,27]. DOK and SCC-
25 cells (5 × 10
5 cells/well) were cultured in complete
medium for 24 h, conditioned medium was harvested
and was concentrated using a Centriplus centrifugal
concentrator (Millipore, Bedford, Massachusetts).
Decorin knock down in DOK and SCC-25 cells in vitro
Silencing of decorin gene expression was achieved using
short hairpin RNA (shRNA) technology. Oligonucleo-
tides targeting decorin transcript variants -A1 (RefSeq
accession no NM_001920, at nucleotide position 720-
740) and -A2 (RefSeq accession no NM_ 133503.2, at
nucleotide position 566-586) and scrambled sequence
non specific to any gene were custom synthesized,
annealed, and cloned into the shRNA expression vector
pGeneClip Puro™ (Promega) by Super Array Bioscience
Corporation (Frederick, MD). BLAST queries were per-
formed to ensure that the sequences have no significant
homology with any other human genes. The transforma-
tion grade shRNAi plasmids were amplified in E. coli
cultures, purified using Midiprep kits for endotoxin-free
DNA vectors and then transfected into DOK and SCC-
25 cells using Effectene™ transfection reagent following
manufacturer’s protocol (Qiagen, Valencia, CA). The
stable transfectants were selected for puromycin (Cal-
biochem, San Diego, CA) antibiotic resistance at 2.5 μg/
ml final optimal concentration. To avoid clone-specific
variances, pools of stable transfectants (maintained at 1
μg/ml of puromycin) were used in all subsequent
experiments. Decorin expression levels were determined
at transcript and protein level by quantitative real-time
reverse transcription-PCR (RT-PCR) and Western blot-
ting, respectively. Hereafter, untransfected DOK and
SCC-25 cells will be referred to as wild type (WT),
scrambled shRNA stable transfectants as control (or
Ctrl-shRNA in figures), and decorin shRNA stable trans-
fectants as decorin silenced (or DCN-shRNA in figures).
Real-time PCR
RNA was extracted from DOK and SCC-25 cells using
RNeasy Plus mini kit (Qiagen, Valencia, CA) and 2.5 μg
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SuperScript III Reverse Transcriptase (Invitrogen, San
Diego, CA). Quantitative RT-PCR was performed using
QuantiTect™ SYBR Green PCR kit (Qiagen, Valencia,
CA) on the Mini Opticon™ Real-Time PCR system
(BioRad, Hercules, CA) as per manufacturer’sp r o t o c o l .
Quantitative PCR primer pairs were designed for SYBR
Green chemistry based detection of amplicons for DCN
(5’-GGACCGTTTCAACAGAGAGG-3’,5 ’-GACCACTC
GAAGATGGCATT-3’), IL-8 (5’-TCTGCAGCTCTG
TGTGAAGG-3’,5 ’-TAATTTCTGTGTTGGCGCAG-3’),
and GAPDH (5’-ACAGTCAGCCGCATCTTCTT-3’,5 ’-
GTTAAAAGCAGCCCTGGTGA-3’). GAPDH was used
as relative house- keeping gene expression control to
normalize for sample variations.
Cell proliferation assay
Cell proliferation was measured using CellTiter 96
® Aqu-
eous One Solution -Cell Proliferation MTS based assay
(Promega, Madison, WI) according to manufacturer’s
instructions. Briefly, WT, control and decorin silenced
DOK and SCC-25 cells (10
5 cells/well), were cultured in
96-well flat-bottom plates at a final volume of a 100 μl for
24, 48, and 72 h. During the last hour of culture 20 μlo f
CellTiter 96
® Aqueous One Solution reagent, containing a
tetrazolium compound [3- (4, 5-dimethylthiazol-2-yl) -5 -
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazo-
lium, inner salt; MTS] and an electron coupling reagent
(phenazine ethosulfate; PES), was added to each well.
Increase in absorbance at 490 nm wavelength (indicating
cell proliferation) was measured using a 96-well plate
reader (SPECTRAMax 190, Molecular Devices, Sunnyvale,
CA) and results were analyzed by SOFTMax Pro software.
Co-Immunoprecipitation and Western Blot Analysis
Cells were rinsed with ice-cold PBS and were lysed in a
buffer containing 20 mM Tris, pH 7.6, 0.1% SDS, 1% Tri-
ton-X, 1% deoxycholate, 100 μg/ml PMSF, and protease
inhibitor cocktail (Sigma-Aldrich, St. Louis, MO). Lysates
were centrifuged at 20,000 × g for 20 min at 4°C. Nuclear
extracts were prepared by using NE-PER kit reagents
(Pierce, Rockford, IL) following manufacturer’sp r o t o c o l .
Protein concentration was determined by Bis-Cinchonic
Acid (BCA) protein assay (Pierce, Rockford, IL) and sub-
jected to 10% SDS-PAGE analysis, followed by transfer to
polyvinylidene difluoride membrane (Bio-Rad, Hercules,
CA). The membranes were immunoprobed with 1:500
dilution of monoclonal anti-human decorin antibody
(Abcam, Cambridge, MA) or 1:1000 dilution of anti-
human b-tubulin polyclonal antibody. Western blots
were developed with appropriate horseradish peroxidase
conjugated secondary antibodies (Bio-Rad) and ECL Plus
chemiluminescence system (Amersham, Arlington
Heights, IL) and exposed to auto radiographic films.
Radiographs were scanned and densitometry analysis was
done using AlphaEase FC software (Alpha Innotech Cor-
poration, San Leandro, CA). For analysis of nuclear
lysates by coimmunoprecpitation, Dynabeads
® Protein G
(Invitrogen, Carlsbad, CA) were used following manufac-
turer’s protocol. Briefly, 5 μg of anti-decorin antibody
was coupled to Dynabeads Protein G and then incubated
with nuclear lysates to capture the target protein (dec-
orin). Immunocomplexes were eluted and were resolved
on 10% SDS-PAGE gel and analyzed by western blotting
(as above) using decorin, EGFR antibodies (Abcam).
ELISA for IL-8 Quantification
Decorin silenced, control and WT DOK and SCC-25
cells (5 × 10
5 cells/well) were cultured in complete med-
ium in 24-well flat-bottom plates at a final volume of a
500 μl. Culture supernatants were collected and IL-8 was
assayed with 100 μl of cell free culture supernatant using
DuoSet IL-8 ELISA kit (R&D Systems, Minneapolis, MN)
according to manufacturer’s instructions. Absorbance
was read at 450 nm with the SPECTRAMax 190 micro-
plate spectrophotometer and results were analyzed by
SOFTMax Pro software (Molecular Devices, Sunnyvale,
CA). Sample concentrations were determined by interpo-
lation from the standard curve. IL-8 detection limit was
found to be 5.6 pg/ml. Samples were read in triplicate.
Cell Migration and Invasion Assay
T h ea b i l i t yo fc e l l st om i g r a t ea c r o s sc o n t r o li n s e r t s
(migration) or invade across Matrigel™- coated inserts
(invasion) was assayed using BD Falcon control inserts or
BD BioCoat Matrigel™ invasion chambers (BD Bios-
ciences, San Jose, CA), respectively. The BD BioCoat
Matrigel™ invasion chambers consist of BD Falcon tissue
culture companion plate with Falcon cell culture inserts
containing 8 micron pore size PET membrane, pre-coated
with a thin layer of Matrigel™ basement membrane
matrix. Manufacturer’s instructions were followed to per-
form the assay. Briefly, serum free DMEM/F12 medium
(0.5 ml) containing 10
5 cells were added to the upper
chamber, and 0.75 ml of DMEM/F12 medium containing
10% serum was added to the lower chamber as a chemo-
attractant. After overnight incubation at 37°C and 5%
CO2, cells on the upper surface of the filter (cells that had
not penetrated the filter) were removed using a cotton
swab. Cells that had migrated to the lower surface of the
filter were fixed in 100% methanol and stained with
0.005% crystal violet. For each filter, the number of
migrated cells in 5 medium-power fields (magnification of
20×) was counted using bright field microscopy, and
photographed. Assays were performed in duplicates and
repeated at least three times. Invasion index is expressed
as percentage of invading cells, and is calculated by divid-
ing mean number of cells invading through Matrigel™
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the non-coated control insert membrane per microscopic
filed over five fields per assay, and ratio then multiplied by
100 for percent values.
Statistical Analysis
Student’s paired t test was used to determine the statistical
significance of the data. Statistical analysis was performed
on Graph Pad Prism Software. Significance was evaluated
at p values: * p < 0.05, ** p < 0.01, *** p < 0.001.
Results
Stable knockdown of decorin using shRNA in DOK and
SCC-25
To study the functional role of aberrantly expressed
nuclear decorin in dysplastic and malignant epithelial
cells, decorin shRNA-stable clones were generated.
Briefly, DNA oligonucleotides specific for decorin mRNA
target sequence and a non-gene scrambled control were
ligated into pGeneClip™ Puro plasmid, and are herein
referred to as decorin shRNA (DCN-shRNA) and control
shRNA (Ctrl-shRNA), respectively. DOK and SCC-25
cells were transfected with these constructs and puromy-
cin resistant positive stable clones were selected. To
avoid clone-specific effects, pooled transfectants were
used for each cell type. Knockdown of decorin expression
was confirmed by real-time PCR and western blot analy-
sis. Pooled decorin-shRNA transfected DOK clones
showed a significant (more than 80%) decrease in decorin
mRNA expression when compared to control-shRNA
transfected clones or no transfection wild type DOK
(Figure 1A). Similar results were observed in SCC-25
cells (Figure 1A). Decorin knock down was also con-
firmed by western blot. Pooled decorin-shRNA trans-
fected DOK or SCC-25 clones showed almost complete
abrogation of decorin protein expression in nuclear
lysates (Figure 1B). Similar decorin protein expression
knock down was observed in whole cell lysates (data not
shown). These results demonstrate that decorin-shRNA
successfully silenced the nuclear decorin expression in
DOK and SCC-25 cells.
Decorin knockdown does not affect cell proliferation in
dysplastic and malignant epithelia
To evaluate the effect of aberrantly expressed nuclear
decorin on the cellular proliferation rates of dysplastic
and malignant oral epithelial cells, DOK and SCC-25 WT
cells, DCN-shRNA transfectants and ctrl-shRNA trans-
fectants were allowed to grow in culture for 24, 48 and
72 h and proliferation was assessed by MTS assay. Com-
pared with WT or control-shRNA cells, decorin silenced
DOK and SCC-25 cells did not show any change in cell
proliferation rates at 24 hrs (Figure 2). Similar results
were obtained at 48 and 72 h time points (data not
shown). This might be due to sequestration of decorin in
the nucleus and consequent inability to interact with
membrane receptors to which extracellular decorin is
known to bind to effect tumor growth in other cancers.
Decorin knockdown mitigates migratory and invasive
phenotype of dysplastic and malignant oral epithelial
cells
We examined whether decorin silencing has any effect
on migration and invasion properties of dysplastic and
malignant oral epithelial cells. Using an in vitro trans
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Figure 1 Validation of stable knockdown of decorin in DOK
and SCC-25 cells. DOK and SCC-25 cells were stably transfected
with decorin-shRNA (DCN-shRNA), or scrambled sequence-shRNA
(Ctrl-shRNA) or no transfection control (WT). A, RNA was extracted
and cDNA was subjected to quantitative RT-PCR, normalized decorin
expression from one representative experiment of three. B, Nuclear
lysates were extracted and were subjected to SDS-PAGE followed
by immunoblotting with anti-decorin and anti-b-tubulin antibodies.
Data presented is one representative immuoblot of at least three
experiments. *** p < 0.001 compared to respective controls.
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observed a significant suppression of cell migration in
both decorin-silenced DOK and SCC-25 cells compared
to respective WT or control cells (Figure 3A &3B).
Next, we determined the invasive property of these cells
as measured through invasion across a Matrigel™
impregnated porous (8 μm) membrane. Invasive pheno-
type was observed to be significantly suppressed in dec-
orin-silenced SCC-25 cells and was almost completely
abrogated in decorin-silenced DOK cells (Figure 3C &
3D). Similar results were obtained when conditioned
media from DOK WT was used as a chemo-attractant
(data not shown). It is important to note that overall
malignant SCC-25 cells have relatively higher migration
and invasion rates than the premalignant and dysplastic
DOK cells.
Attenuation of IL-8 production in decorin silenced DOK
and SCC25 cells
IL-8 is an important pro-inflammatory chemokine and is
involved in tumor progression in a variety of malignan-
cies. In particular, IL-8 has been shown to induce
migration and invasion in oral squamous cell carcinoma
cell lines[23]. Moreover, decorin has been shown to
induce IL-8 production in endothelial cells [25]. There-
fore, we sought to determine if nuclear decorin silencing
has an effect on IL-8 production in these dysplastic and
malignant oral epithelial cells. Interestingly, IL-8 expres-
sion was significantly reduced in nuclear decorin-
silenced DOK or SCC-25 cells as compared to the
control and WT cells. Real-time PCR analysis revealed
over 90% reduction in constitutive IL-8 expression in
decorin-silenced DOK and about 70% reduction in dec-
orin-silenced SCC-25 cells (Figure 4A). IL-8 protein
production, as measured by ELISA, was found to be sig-
nificantly reduced in decorin-silenced DOK and SCC-25
cells (Figure 4B). However, as observed with IL-8
expression levels, the effect of decorin silencing on IL-8
production was more pronounced in DOK than in SCC-
25 cells.
Supplementation with IL8 rescues migration and invasion
suppression in decorin silenced cell lines
Next, we sought to determine whether diminished migra-
tion and invasion in decorin-silenced DOK and SCC-25
cells was due to reduced IL-8 expression. Decorin
silenced DOK and SCC-25 cells were cultured with 2.5-
5.0 ng/ml of recombinant human IL-8 (rIL-8) or condi-
tioned medium from respective un-transfected (wild
type) cell lines for 24 h prior to migration and invasion
assay. As shown in Figure 5A and 5B, both migratory and
invasive phenotype of decorin silenced dysplastic and
malignant oral epithelial cells was salvaged by pre-incu-
bation with rIL-8 or IL-8 containing conditioned medium
emphasising the role played by this cytokine in this phe-
nomenon. Similar results were obtained for 5.0 ng/ml
rIL-8 (data not shown).
Decorin is associated with EGFR in the nuclear
compartment
We have previously shown that decorin is aberrantly
expressed and localized to the nucleus in DOK and SCC-
25. However, decorin is not known to carry nuclear loca-
lization signal. In an effort to identify possible binding
partners of decorin in the nucleus of these dysplastic and
malignant oral epithelial cells, we explored weather
nuclear decorin physically associates with nuclear EGFR.
Nuclear lysates were obtained from DOK and SCC-25
cells. Interestingly, immunoprecipitation with decorin
antibody co-precipitated EGFR in both dysplastic (DOK)
and malignant (SCC-25) oral epithelial cells (Figure 6).
However, similar immunoprecpitation with decorin anti-
body did not co-precipitate either biglycan or LRRFIP2,
the other two suspect NLS carrying proteins (data not
shown). Our results suggest that nuclear localized dec-
orin interacts with nuclear localized EGFR in these dys-
plastic and malignant oral epithelial cells. Intriguingly,
Figure 2 Decorin silencing does not affect DOK or SCC-25 cell
growth/proliferation. WT, control and decorin silenced DOK and
SCC-25 cells were cultured for 24 h. During the last hour of culture,
20 μl of CellTiter 96
® Aqueous One Solution Reagent containing a
tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt;
MTS] and an electron coupling reagent (phenazine ethosulfate; PES)
was added to the media (100 μl per well), and color changes were
recorded by absorbance at 490 nm. Data are presented as mean ±
SE of three replicates of one representative experiment of three.
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Figure 3 Migration and invasion suppression in decorin silenced cell lines. A, Cell motility through uncoated filters (migration) was
measured 22 h after plating. The migrating cells were fixed, stained, and photographed as described in materials and methods. Each panel
represents one representative field of five from duplicate filters of three experiments. B, Migrated cells in each one of the five fields of duplicate
filters were counted, numbers represent mean ± SD of three experiments. C, Cells that invaded across the Matrigel™ layer were fixed, stained,
and photographed. Each panel represents one representative field of five from duplicate filters of three experiments. D, Migrated and invaded
cells in five fields of duplicate filters were counted and % invasion was calculated as described in materials and methods. Numbers represent
mean ± SD of three individual experiments. ** p < 0.01, *** p < 0.001 compared to respective controls.
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production in epithelial cells [28,29].
Discussion
Decorin, a multifunctional molecule of the extracellular
matrix, has been assigned a plethora of functions. Among
these, the most intriguing is the ability to inhibit growth
and metastasis of a wide range of cancer cells in vitro.
Functions of decorin as a naturally occurring oncosup-
pressive agent are being studied in detail. Decorin is nor-
mally present in the extracellular stromal compartment
and analysis of a variety of tumours indicates that it is
seldom expressed by cancer tissue. However studies by
us and others have demonstrated that there are excep-
tions to this prevailing decorin expression and decorin
mediated growth suppression model in cancer. In our
previous studies of oral precancerous and cancerous
lesions and cellular models of oral cancer progression, we
demonstrated that decorin is aberrantly expressed and
localized in the nucleus in the dysplastic and malignant
oral epithelial cells [20]. In this study we used shRNA
expression plasmid mediated in vitro stable gene silen-
cing in DOK and SCC-25 cells to study the role of
nuclear localized decorin in oral cancer.
The ability of a cancer cell to undergo migration and
invasion allows it to change position within the tissues
allowing neoplastic cells to enter lymphatic and blood
vessels for dissemination into the circulation, and then
undergo metastatic growth in distant organs. Using an in
vitro Matrigel™ coated and uncoated Trans well cham-
ber based invasion and migration assay, we find here that
nuclear decorin silencing results in impaired invasive and
migratory potential in both dysplastic and malignant oral
epithelia. It is interesting to note that in osteosarcoma
cells, decorin was also found to be necessary for cell
migration [21]. Moreover, these Osteosarcoma cells have
also been shown to constitutively produce decorin and
manifest resistance to decorin induced growth arrest.
Growth and motility of various cancer cells is influenced
by assorted growth factors, cytokines and chemokines.
Recently, there has been increasing evidence that chemo-
kines have a role in tumor biology. Chemokines were first
described as small peptides controlling cell migration,
especially that of leukocytes during inflammation and
immune response. Since then, a broad spectrum of biolo-
gical activities has been described as chemokine-regulated
tumorigenesis that effect tumors and their microenviron-
ment. Increased expression of IL-8 and/or its receptors
has been characterized in cancer cells, endothelial cells,
infiltrating neutrophils, and tumor-associated macro-
phages, suggesting that IL-8 may function as a significant
regulatory factor within the tumor microenvironment.
Many tumor cells, such as prostate carcinoma, melanoma,
breast carcinoma and gastric carcinoma cell lines, respond
B. A.
Figure 4 Reduced IL-8 production in decorin Silenced DOK and SCC25. A, RNA was extracted from WT, control and decorin silenced DOK
and SCC-25 cells and cDNA was subjected to quantitative RT-PCR, normalized IL-8 expression from one representative experiment of three. B,
Cells were cultured and IL-8 was measured in 24 h culture supernatants using ELISA. Data are presented as mean ± SD of three replicates of one
representative experiment of four. ** p < 0.01, *** p < 0.001 compared to respective controls.
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autocrine growth factor for melanoma, colon carcinoma,
lung adenocarcinoma and prostate carcinoma cell lines
[35-38]. In addition, IL-8 has been shown to be produced
by oral squamous cell carcinoma both constitutively and
in response to cytokines[23]. In these oral carcinoma cell
lines, IL-8 was shown to have positive influence on migra-
tion and invasion via up-regulation of MMP-7. Given the
importance of IL-8 in tumor migration and invasion, we
tested whether IL-8 was involved in nuclear decorin silen-
cing mediated migration and invasion suppression in our
system. We found that, IL-8 production was significantly
attenuated in nuclear decorin silenced DOK and SCC25
cells. Rescue of migration and invasion suppression upon
addition of exogenous IL8 indicates that reduced IL-8
might be forming the basis of migration and invasion miti-
gation in these decorin silenced cell lines. Whether or not
there is a direct or indirect relationship between decorin
and IL-8 is not known currently and needs further
exploration. However, intriguingly, decorin has been
shown to induce IL-8 production at least in endothelial
cells [25].
We have previously shown that decorin is aberrantly
expressed in the nucleus in DOK and SCC-25 oral cell
lines and human biopsy tissues [20]. However, underlying
mechanism by which decorin localizes to the nucleus in
these cells is unclear. Decorin lacks nuclear localization
signal (NLS), hence it might be binding with another pro-
tein that carries NLS thus providing a means for decorin
to localize to the nucleus in the oral cells. Elucidation of
potential interactions of the aberrant decorin expressed
in the oral cancer progression model and its biological
implications need to be addressed further. As such, in
this study we explored the possible nuclear decorin bind-
ing partners by immuoprecipitation experiments on
nuclear lysates obtained from DOK and SCC-25 cells.
Decorin is a known alternate biological ligand for EGFR,
other than EGF [11]. It binds t oad i s c r e t er e g i o no ft h e
EGFR which is partially overlapping but distinct from the
A.
B.
Figure 5 Migration and invasion suppression rescued by
addition of IL8 in decorin silenced cell lines. Decorin silenced
DOK and SCC-25 cells were cultured with 2.5 ng/ml of recombinant
human IL-8 (R&D Systems, Minneapolis, MN) or conditioned
medium (CM) from respective wild type cell lines for 24 h prior to
migration and invasion assay. A, Cell motility through uncoated
filters (migration) was measured 22 h after plating. The migrating
cells were fixed, stained, and photographed as described in
materials and methods. A, Migrated cells in each one of the five
fields of duplicate filters were counted, numbers represent mean ±
SD of three experiments. B, Cells that invaded across the Matrigel™
layer were fixed, stained, and photographed. Migrated and invaded
cells in five fields of duplicate filters were counted and % invasion
was calculated as described in materials and methods. Numbers
represent mean ± SD of three individual experiments. * p < 0.05, **
p < 0.01, *** p < 0.001 compared to respective controls.
IP
No Ab Input Decorin
IB: EGFR
IB: Decorin
Figure 6 Nuclear Decorin associates with EGFR. Nuclear lysates
were extracted from DOK and SCC-25 cells and were
immunoprecipitated (IP) with decorin antibody. Immunocomplexes
were subjected to SDS-PAGE and were analysed by immunoblotting
(IB) with anti-decorin and anti-EGFR antibodies.
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Page 8 of 10EGF-binding domain [12]. Emerging evidence suggests
that EGFR family carries NLS and either full length or
fragmented EGFR family members can be shuttled from
the plasma membranes to the nucleus [39-41]. This
direct mode of the EGFR signaling pathway is distinct
from the traditional transduction pathway and involves
cellular transport of EGFR from the cell-surface to the
cell nucleus, association of nuclear EGFR with transcrip-
tional co-factors and target gene promoters, and tran-
scriptional regulation of the target genes. Aberrant
expression and nuclear localization of EGFR has been
demonstrated by many different groups in a variety of
human cancers including oral cancer [42-44]. Mutant
EGFR, a truncated EGFR variant (EGFRvIII), has also
been described in head and neck cancer [45]. In search of
a possible mechanism by which decorin is aberrantly
localized in the nucleus, we sought out to determine if
nuclear decorin interacts with nuclear EGFR in our oral
cancer model. We found that EGFR is expressed in the
nuclear lysates obtained from DOK and SCC-25 cells,
and very interestingly, results of our co- immunoprecipi-
tation experiments demonstrate that nuclear decorin
does interacts with nuclear EGFR in these dysplastic and
malignant oral epithelia. This indicates a possible means
by which decorin is aberrantly localized in the nuclei in
our oral cancer model. As mentioned above, nuclear
EGFR has been shown to act as transcription factor and
its transcriptional activity appears to depend on its C-
terminal transactivation domain and its physical and
functional interaction with other transcription factors
that contain DNA-binding activity [46]. Interestingly,
EGFR (trans) activation has been shown to be involved in
IL-8 production in lung and skin epithelia [28,47].
Whether or not nuclear EGFR has direct or indirect role
in IL-8 transcription is not known currently. Besides dec-
orin-EGFR relation, additional interactions with other
nuclear and/or cytosolic factors may result from the
aberrant localization of decorin and perhaps result in
some of decorin’s tumor-promoting role in oral cancer.
Together, results from our study suggest the importance
of decorin as a potential therapeutic target in oral cancer,
as it modulates migration and invasion of premalignant
and malignant oral epithelial cells. Further mechanistic
studies are warranted to decipher how IL-8 expression is
regulated by nuclear localization of decorin and/or its
interaction with EGFR in these cells. Studies in our
laboratory are underway in this direction which will shed
light on additional biological aspects of nuclear localized
decorin in oral cancer progression.
Conclusions
Using shRNA expression plasmid mediated in vitro
stable gene silencing in dysplastic and malignant oral
e p i t h e l i a lc e l l s ;w ep r e s e n th e r eas t u d yo ft h er o l eo f
nuclear localized decorin in oral cancer progression. We
demonstrate that nuclear localized decorin knockdown
suppresses migration and invasion in DOK and SCC-25
cells. Our data also indicate that reduced migration and
invasion phenotype of these cells is perhaps mediated by
IL-8 modulation. Furthermore, we show here that
nuclear localized decorin interacts with nuclear EGFR in
this oral cancer cell line model. The results of our study
highlight the importance of decorin as a potential oral
cancer specific therapeutic target.
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